Bayer’s Xarelto Backed in Final Stroke Guidance From U.K.’s NICE
The U.K.’s National Institute for Health and Clinical Excellence published final guidance recommending Bayer AG (BAYN)’s Xarelto blood-thinner as a cost- effective way to prevent strokes in people with an irregular heartbeat known as atrial fibrillation.
Deciding whether to start treatment with the drug should be made after the patient and physician have discussed Xarelto’s risks and benefits compared with warfarin, an older treatment, the health-cost agency, known as NICE, said today in an e-mailed statement.
To contact the reporter on this story: Kristen Hallam in London at email@example.com
To contact the editor responsible for this story: Kristen Hallam at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.